Overview

A Phase 3 Clinical Study of KHK4827

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate safety and efficacy of long-term exposure of KHK4827 in subjects with moderate to severe plaque psoriasis who have completed the preceding Study 4827-002.
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited
Kyowa Kirin Co., Ltd.
Treatments:
Brodalumab